Kopp Investment Advisors LLC Increases Stake in NxStage Medical, Inc. (NXTM)
Kopp Investment Advisors LLC grew its holdings in shares of NxStage Medical, Inc. (NASDAQ:NXTM) by 11.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 104,360 shares of the medical device company’s stock after buying an additional 10,472 shares during the period. NxStage Medical accounts for approximately 2.5% of Kopp Investment Advisors LLC’s holdings, making the stock its 18th biggest position. Kopp Investment Advisors LLC’s holdings in NxStage Medical were worth $2,912,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Tokio Marine Asset Management Co. Ltd. bought a new stake in shares of NxStage Medical during the 2nd quarter valued at $1,038,000. Commonwealth Equity Services LLC bought a new position in NxStage Medical in the 2nd quarter worth about $373,000. Ontario Teachers Pension Plan Board bought a new position in NxStage Medical in the 2nd quarter worth about $1,674,000. Alpine Associates Management Inc. boosted its stake in NxStage Medical by 0.9% in the 2nd quarter. Alpine Associates Management Inc. now owns 3,326,982 shares of the medical device company’s stock worth $93,087,000 after purchasing an additional 30,300 shares in the last quarter. Finally, Mint Tower Capital Management B.V. bought a new position in NxStage Medical in the 2nd quarter worth about $488,000. Hedge funds and other institutional investors own 83.23% of the company’s stock.
A number of brokerages recently issued reports on NXTM. BidaskClub upgraded shares of NxStage Medical from a “sell” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a research note on Saturday, August 11th. Finally, ValuEngine cut shares of NxStage Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $30.00.
NxStage Medical Company Profile
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.